More than anything, Peter Thiel, the billionaire technology investor and Donald Trump supporter, wants to find a way to escape death.
He's channeled millions of dollars into startups working on anti-aging medicine, spends considerable time and money researching therapies for his personal use and believes society ought to open its mind toward life-extension methods that sound weird or unsavory.
Speaking of weird and unsavoury, if there's one thing that really excites Thiel, it's the prospect of having younger people's blood transfused into his own veins.
That practice is known as parabiosis, and, according to Thiel, it's a potential biological Fountain of Youth--the closest thing science has discovered to an anti-aging panacea. Research into parabiosis began in the 1950s with crude experiments that involved cutting rats open and stitching their circulatory systems together. After decades languishing on the fringes, it's recently started getting attention from mainstream researchers, with multiple clinical trials underway in humans in the U.S. and even more advanced studies in China and Korea.
There are widespread rumors in Silicon Valley, where life-extension science is a popular obsession, that various wealthy individuals from the tech world have already begun practicing parabiosis, spending tens of thousands of dollars for the procedures and young-person-blood, and repeating the exercise several times a year. In our April 2015 interview, Thiel was seemingly explicit that parabiosis was something he hadn't "quite, quite, quite started yet." A Thiel Capital spokesman said nothing had changed since then.
Anyone seeking to practice parabiosis privately would quickly encounter the question of where to obtain sufficient quantities of young people's blood. But human blood isn't available for purchase to just anybody.
A spokeswoman for the Food and Drug Administration says the agency "regulates the collection and manufacture of blood and blood components to help protect the health of the blood donor and to ensure the safety, purity and potency of the blood product." While it's not approved specifically for anti-aging treatments, like other drugs, it can be prescribed for so-called off-label uses as long as there is no advertising or efficacy claims involved.
Clinical trials like Ambrosia's can get blood from blood banks fairly easily for that purpose, but Ambrosia is a for-profit company. For it to begin selling transfusions as a service to patient clients like Thiel, it would presumably need to figure out a source other than non-profit blood banks.
Karmazin acknowledges the potential supply issue, but notes that plasma is relatively abundant and has a two-year shelf life. He speculates that a surge of popular attention for parabiosis might inspire more blood donations by young donors, whose blood tends to provide greater benefit when administered in more conventional therapeutic transfusions.
For Thiel, the day when technologies like parabiosis are not only clinically proven but socially accepted can't come soon enough.
After all, he's not getting any younger.
http://www.businessinsider.com/peter-thiel-interested-in-young-blood-2016-8?IR=T
Not quite sure if such developments are really worth it. The issue is not gonna help when there are already too many humans on this planet. Death is natural, so is ageing. With already not enough blood on blood banks, wasting blood for the rich is rather cynical.